Skip to main navigation

Skip to Content

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Stock Information
Financials
- SEC Filings
Resources

News Releases

Year

Nov 13, 2023

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 08, 2023

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 07, 2023

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Sep 18, 2023

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 06, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Sep 05, 2023

Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 10, 2023

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 07, 2023

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Jul 24, 2023

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Print

RSS Feeds

Email Alerts

Contact IR

Tango Therapeutics, Inc
201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
Tel: +1-857-320-4900

contact | careers |